BioRestorative Therapies, Inc. financial data

Symbol
BRTX on Nasdaq
Location
Melville, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 218% % -38.58%
Debt-to-equity 55% % 75%
Return On Equity -233% % -173.8%
Return On Assets -138% % -118.82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,876,242 shares 28%
Common Stock, Shares, Outstanding 7,978,117 shares 15%
Entity Public Float $11,463,696 USD -16.1%
Common Stock, Value, Issued $797 USD 15%
Weighted Average Number of Shares Outstanding, Basic 9,116,172 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 9,116,172 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $383,400 USD 1.7%
Research and Development Expense $7,918,174 USD 57%
General and Administrative Expense $6,951,653 USD -5.83%
Operating Income (Loss) $-14,511,974 USD -20.08%
Nonoperating Income (Expense) $1,841,487 USD -24.48%
Net Income (Loss) Attributable to Parent $-12,670,487 USD -31.34%
Earnings Per Share, Basic -1 USD/shares -37.38%
Earnings Per Share, Diluted -1 USD/shares -250%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $602,444 USD -59.55%
Marketable Securities, Current $3,887,383 USD -66.48%
Accounts Receivable, after Allowance for Credit Loss, Current $13,400 USD -91.88%
Assets, Current $4,707,464 USD -65.15%
Property, Plant and Equipment, Net $309,498 USD -18.22%
Operating Lease, Right-of-Use Asset $39,697 USD -74.34%
Intangible Assets, Net (Excluding Goodwill) $556,634 USD -13.88%
Assets $5,642,662 USD -61.28%
Accounts Payable, Current $859,898 USD 114%
Employee-related Liabilities, Current $538,875 USD
Accrued Liabilities, Current $744,485 USD 4.6%
Contract with Customer, Liability, Current $150,000 USD
Liabilities, Current $3,435,683 USD -25.01%
Liabilities $3,671,235 USD -30.99%
Retained Earnings (Accumulated Deficit) $-166,713,054 USD -8.22%
Stockholders' Equity Attributable to Parent $2,206,979 USD -77.91%
Liabilities and Equity $5,642,662 USD -61.28%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $-2,778,786 USD -19.89%
Net Cash Provided by (Used in) Financing Activities $1,092,718 USD -85.47%
Net Cash Provided by (Used in) Investing Activities $2,366,967 USD
Common Stock, Shares Authorized 75,000,000 shares 0%
Common Stock, Shares, Issued 7,978,117 shares 15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $680,899 USD 150%
Deferred Tax Assets, Valuation Allowance $29,434,100 USD -7.56%
Deferred Tax Assets, Gross $29,724,000 USD -7.5%
Operating Lease, Liability $42,414 USD -78.66%
Payments to Acquire Property, Plant, and Equipment $36,400 USD
Lessee, Operating Lease, Liability, to be Paid $43,265 USD -79.88%
Property, Plant and Equipment, Gross $1,474,072 USD 7.8%
Operating Lease, Liability, Current $42,414 USD -72.86%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $851 USD -94.79%
Deferred Tax Assets, Operating Loss Carryforwards $18,004,100 USD 26%
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Operating Lease, Payments $43,265 USD 3%
Additional Paid in Capital $168,905,254 USD 3%
Share-based Payment Arrangement, Expense $3,053,391 USD -24.83%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%